The Caldwells’ triumph, however, was short-lived. Just a few days after Evelyn’s grand announcement, a strange undercurrent of anxiety began to ripple through Crestwood General. It started subtly, with minor inconveniences. A delay in the delivery of surgical sponges. A backorder on a specific type of suture material.
Then, the whispers began to grow louder. Nurses complained about shortages in the supply closets. Residents grumbled about delays in receiving essential diagnostic kits. The sterile processing department was running behind, citing issues with equipment maintenance and spare parts.
I noticed it in my own work. A requested piece of imaging equipment for a post-op consultation was mysteriously unavailable. When I inquired, the tech simply shrugged, “Supply chain issues, Dr. Sharma. Orders are being held up. No one knows why.”
Then came the memos. Urgent, confidential, marked “For Department Heads Only” and then “For All Staff.” They cited “unforeseen supply chain disruptions” and “immediate funding re-evaluations.” The language was bureaucratic, but the implications were clear and terrifying.
One morning, the Chief of Anesthesiology cornered Dr. Lena Khan, his face pale. “Lena, my orders for advanced anesthesia agents have been flagged. They’re saying they can’t fulfill them for three weeks! How are we supposed to perform complex surgeries without critical agents?”
Lena’s brow was furrowed. “I just got a similar notification about our new endoscopic equipment orders. Completely halted. They’re blaming a ‘vendor issue’.”
The “vendor issue” was a blanket term, used to cover a growing multitude of problems. The new “exclusive partnership” with Vitalis Medical Solutions, heralded by Evelyn, was clearly not living up to its promise. Instead, it seemed to be causing chaos.
Later that day, I overheard Leo in the cafeteria, agitated, speaking rapidly into his phone. “What do you mean the grant is on hold? My research cannot be put on indefinite hiatus! We’re weeks away from a major breakthrough!”
His face was flushed, a stark contrast to his usual cool demeanor. He slammed his phone down. When he looked up and saw me, his expression tightened, but he didn’t try to hide his frustration.
“Having problems, Dr. Caldwell?” I asked, my voice neutral.
He scowled. “My entire research initiative is being held hostage. Apparently, the funding from the Caldwell Foundation for my cardiology projects is under ‘re-evaluation.’ And Vitalis Medical Solutions can’t even supply the basic equipment we need for ongoing trials.” His voice dripped with disbelief. “It’s absurd. My mother just announced a seventy-five-million-dollar deal with them.”
I simply nodded, a slow, dawning realization washing over me. This was more than just supplier problems. This was a hospital-wide supply and funding crisis. And it was hitting the Caldwells directly where it hurt: their reputation, their projects, and their financial control.
The gravity of the situation escalated rapidly. Dr. Kincaid, looking haggard and visibly stressed, called an emergency meeting of all department heads in the main conference room. I was not invited, but Lena shared the details with me afterward.
“It was a complete mess, Anya,” she reported, leaning against the wall outside my on-call room. “Kincaid looked like he’d aged ten years. Everyone was complaining. Orthopedics can’t get specific joint replacements. Oncology is struggling to source chemo drip bags. Pharmacy is running low on common antibiotics. And then there’s the research funding.”
“Leo’s projects?” I asked.
Lena nodded. “He was furious. His entire department is impacted. Kincaid kept saying it was an ‘unforeseen disruption’ and a ‘bureaucratic snafu’ with Vitalis, but no one bought it. Something big is going on. They have no idea why their cash flow and supply lines have suddenly dried up.”
“Did anyone mention the Caldwell Foundation?” I probed, trying to sound casual.
“Kincaid did, in passing,” Lena confirmed. “He mentioned that the primary account for the Vitalis payments, which is managed through the Foundation, has apparently been ‘flagged for review.’ He seemed completely baffled. Said he had a call with Mr. Davies, the accountant, but even Davies couldn’t provide a clear explanation, only vague corporate speak about ‘internal ethical audits’.”
An internal ethical audit. The phrase resonated with me. My mother’s company, BioInnovate Global, was known for its stringent ethical clauses. They were ruthless about upholding their corporate standards. Could this be more than just a coincidence?
My mother had said she would “think.” Was this what she meant? A sudden, strategic squeeze on the hospital’s vital organs, aimed directly at the Caldwells’ source of power?
The confusion among the hospital board, the department heads, and even the Caldwells themselves was almost comical in its scale. They were completely blind to the true source of their woes, thinking it was a mere logistical problem. They believed their seventy-five-million-dollar deal had made them untouchable. They believed their control was absolute.
But the cracks were appearing, deep and wide, in the very foundation of their power. The exclusive deal, the golden handcuffs they thought they had placed on the hospital, were slowly turning into a weapon aimed squarely at them. And I, the humiliated resident, was starting to feel a flicker of hope, a surge of adrenaline I hadn’t felt in weeks. The game wasn’t over. It had only just begun. The Caldwells were about to learn that some ethical clauses could be very, very expensive.
+ There are no comments
Add yours